113 related articles for article (PubMed ID: 32699017)
1. Tumor-related mutations in cell-free DNA in pre-operative plasma as a prognostic indicator of recurrence in endometrial cancer.
Shintani D; Hihara T; Ogasawara A; Sato S; Yabuno A; Tai K; Fujiwara K; Watanabe K; Hasegawa K
Int J Gynecol Cancer; 2020 Sep; 30(9):1340-1346. PubMed ID: 32699017
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.
Ogasawara A; Hihara T; Shintani D; Yabuno A; Ikeda Y; Tai K; Fujiwara K; Watanabe K; Hasegawa K
Cancer Res Treat; 2020 Oct; 52(4):1219-1228. PubMed ID: 32599986
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.
Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W
J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036
[TBL] [Abstract][Full Text] [Related]
4. Pre-operative plasma cell-free circulating tumor DNA and serum protein tumor markers as predictors of lung adenocarcinoma recurrence.
Isaksson S; George AM; Jönsson M; Cirenajwis H; Jönsson P; Bendahl PO; Brunnström H; Staaf J; Saal LH; Planck M
Acta Oncol; 2019 Aug; 58(8):1079-1086. PubMed ID: 31230502
[No Abstract] [Full Text] [Related]
5. Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction.
Lee JS; Kim M; Seong MW; Kim HS; Lee YK; Kang HJ
Clin Chem Lab Med; 2020 Mar; 58(4):527-532. PubMed ID: 31874093
[TBL] [Abstract][Full Text] [Related]
6. Personalized tumor-specific DNA junctions to detect circulating tumor in patients with endometrial cancer.
Grassi T; Harris FR; Smadbeck JB; Murphy SJ; Block MS; Multinu F; Schaefer Klein JL; Zhang P; Karagouga G; Liu MC; Larish A; Lemens MA; Sommerfield MKS; Cappuccio S; Cheville JC; Vasmatzis G; Mariani A
PLoS One; 2021; 16(6):e0252390. PubMed ID: 34111149
[TBL] [Abstract][Full Text] [Related]
7. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers.
Bellone S; McNamara B; Mutlu L; Demirkiran C; Hartwich TMP; Harold J; Yang-Hartwich Y; Siegel ER; Santin AD
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240216
[TBL] [Abstract][Full Text] [Related]
8. Targeted next-generation sequencing of endometrial cancer and matched circulating tumor DNA: identification of plasma-based, tumor-associated mutations in early stage patients.
Bolivar AM; Luthra R; Mehrotra M; Chen W; Barkoh BA; Hu P; Zhang W; Broaddus RR
Mod Pathol; 2019 Mar; 32(3):405-414. PubMed ID: 30315273
[TBL] [Abstract][Full Text] [Related]
9. Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay.
Lyu N; Rajendran VK; Diefenbach RJ; Charles K; Clarke SJ; Engel A; ; Rizos H; Molloy MP; Wang Y
Nanotheranostics; 2020; 4(4):224-232. PubMed ID: 32923312
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
[TBL] [Abstract][Full Text] [Related]
11. Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.
Kodahl AR; Ehmsen S; Pallisgaard N; Jylling AMB; Jensen JD; Laenkholm AV; Knoop AS; Ditzel HJ
Mol Oncol; 2018 Jun; 12(6):925-935. PubMed ID: 29689598
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation.
Cho MS; Park CH; Lee S; Park HS
PLoS One; 2020; 15(3):e0230622. PubMed ID: 32196518
[TBL] [Abstract][Full Text] [Related]
14. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E
Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443
[TBL] [Abstract][Full Text] [Related]
16. Preoperative detection of KRAS mutated circulating tumor DNA is an independent risk factor for recurrence in colorectal cancer.
Nakamura Y; Yokoyama S; Matsuda K; Tamura K; Mitani Y; Iwamoto H; Mizumoto Y; Murakami D; Kitahata Y; Yamaue H
Sci Rep; 2021 Jan; 11(1):441. PubMed ID: 33432066
[TBL] [Abstract][Full Text] [Related]
17. Detection of somatic mutations in peritoneal lavages and plasma of endometrial cancer patients: A proof-of-concept study.
Mayo-de-Las-Casas C; Velasco A; Sanchez D; Martínez-Bueno A; Garzón-Ibáñez M; Gatius S; Ruiz-Miró M; Gonzalez-Tallada X; Llordella I; Tresserra F; Rodríguez S; Aldeguer E; Roman-Canal B; Bertran-Alamillo J; García-Peláez B; Rosell R; Molina-Vila MA; Matias-Guiu X
Int J Cancer; 2020 Jul; 147(1):277-284. PubMed ID: 31953839
[TBL] [Abstract][Full Text] [Related]
18. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
19. Impact of uterine manipulator on oncological outcome in endometrial cancer surgery.
Padilla-Iserte P; Lago V; Tauste C; Díaz-Feijoo B; Gil-Moreno A; Oliver R; Coronado P; Martín-Salamanca MB; Pantoja-Garrido M; Marcos-Sanmartin J; Gilabert-Estellés J; Lorenzo C; Cazorla E; Roldán-Rivas F; Rodríguez-Hernández JR; Sánchez L; Muruzábal JC; Hervas D; Domingo S;
Am J Obstet Gynecol; 2021 Jan; 224(1):65.e1-65.e11. PubMed ID: 32693096
[TBL] [Abstract][Full Text] [Related]
20. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
